Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | CD4 | P01730 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12169347 | 0.90 | PKM (0.65) | PKMHTTALDH1A1POLBCD4 | |
| SCHEMBL2448500 | 0.89 | PKM (0.70) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL505093 | 0.89 | KMT2A (0.69) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL17369299 | 0.89 | PKM (0.64) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL11605844 | 0.85 | PKM (0.63) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL6559970 | 0.83 | KMT2A (0.56) | PKMALDH1A1KMT2AMMP2MEN1 | |
| SCHEMBL12330050 | 0.83 | PKM (0.61) | PKMHTTALDH1A1POLBCD4 | |
| SCHEMBL8024905 | 0.82 | KMT2A (0.64) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL9693041 | 0.80 | PKM (0.66) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL4537086 | 0.79 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190321313-A1 | BENZENESULFONAMIDE DERIVATIVES AND METHOD FOR TREATING CANCER | Gongwin Biopharm Holdings Co., Ltd. | 2019-10-24 | — | — | US | disclosed |
| US-9782370-B2 | Pharmaceutical compositions of benzenesulfonamide derivatives for treatment of adenoid cystic carcinoma | Gongwin Biopharm Holdings Co., Ltd. (KY) | 2017-10-10 | — | — | US | disclosed |
| US-20170172951-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS OF BENZENESULFONAMIDE DERIVATIVES FOR TREATMENT OF ADENOID CYSTIC CARCINOMA | GONGWIN BIOPHARM CO., LTD. (TAIWAN) (TW) | 2017-06-22 | — | — | US | disclosed |
| US-8431378-B2 | Aminotransferase, gene encoding the same, and methods of using them | KANEKA CORPORATION (JP) | 2013-04-30 | — | — | US | disclosed |
| US-20120164724-A1 | NOVEL AMINOTRANSFERASE, GENE ENCODING THE SAME, AND METHODS OF USING THEM | KANEKA CORPORATION (JP) | 2012-06-28 | — | — | US | disclosed |
| US-8133705-B2 | Aminotransferase, gene encoding the same, and method of using them | KANEKA CORPORATION (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8039467-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039467-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100285544-A1 | Novel aminotransferase, gene encoding the same, and method of using them | KANEKA CORPORATION (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20100145048-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| EP-1889907-B1 | NOVEL AMINO GROUP TRANSFERASE, GENE ENCODING THE SAME AND METHOD OF USING THE SAME | KANEKA CORP (JP) | 2009-09-02 | — | — | EP | disclosed |
| EP-1889907-A1 | NOVEL AMINO GROUP TRANSFERASE, GENE ENCODING THE SAME AND METHOD OF USING THE SAME | Kaneka Corporation (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| WO-2007064749-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND MICROBIAL DISEASES | SCHERING CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
| WO-2005121130-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | PKM 2433/4885HTT 1008/4885ALDH1A1 1502/4885 |
| US-20190321313-A1 | BENZENESULFONAMIDE DERIVATIVES AND METHOD FOR TREATING CANCER | ARSA, ABCB1, ABCG2 | PKM 1749/4885HTT 902/4885ALDH1A1 689/4885 |
| US-20170172951-A1 | NOVEL PHARMACEUTICAL COMPOSITIONS OF BENZENESULFONAMIDE DERIVATIVES FOR TREATMENT OF ADENOID CYSTIC CARCINOMA | ABCD3, CFTR, ADSL | PKM 3549/4885HTT 2849/4885ALDH1A1 1243/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | PKM 2167/4885HTT 1281/4885ALDH1A1 1369/4885 |
| US-20100145048-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, MMP12, MMP8 | PKM 2069/4885HTT 1719/4885ALDH1A1 1342/4885 |
| US-20100285544-A1 | Novel aminotransferase, gene encoding the same, and method of using them | BCAT1, AGXT, ALDH7A1 | PKM 424/4885HTT 2680/4885ALDH1A1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.